Grail Stock Sinks 50% After Cancer-Screening Trial Misses Primary Endpoint
Grail’s stock plunged 50% after its pivotal multi-cancer screening trial failed to meet the primary endpoint, erasing roughly half of its market value in one session. The selloff came despite the company reporting fourth-quarter revenue and non-GAAP earnings above analyst estimates.
1. Pivotal Trial Misses Primary Endpoint
Grail’s flagship cancer-screening study failed to achieve its pre-specified primary endpoint, falling short of sensitivity and specificity targets required for clinical validation. The unexpected result prompted management to pause further patient enrollment and reevaluate the assay’s design.
2. Fourth-Quarter Earnings Beat
In the fourth quarter, Grail reported revenue and non-GAAP earnings that exceeded consensus forecasts, marking another period of financial outperformance. Despite this, the positive financial metrics were overshadowed by the trial setback, which raises questions about future profitability.
3. Investor Selloff and Market Impact
Shares collapsed nearly 50% in a single trading day, wiping out billions in market capitalization as investors reassessed the risk profile of Grail’s pipeline. The rapid decline underscores concerns over the viability of the company’s core diagnostic technology going forward.